Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,122 stopped studies mapped to Lung Non-Small Cell Carcinoma and descendants · 90% state a reason
Over the 1,122 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients… | Phase 3 | terminated | May 30, 2007 | GlaxoSmithKline | The study was terminated following assessment of the lack of efficacy of the study product by the… | Efficacy / futility |
| NCT03603652 | NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of… | N/A | terminated | Jul 27, 2018 | Ethicon, Inc. | Study originally suspended pending a protocol amendment but study now terminated. | Other (stated, no rule matched) |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | Phase 1 | terminated | Aug 11, 2017 | National Health Research Institutes, Taiwan | No more funding | Funding |
| NCT04576208 | A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related… | Phase 2 | withdrawn | Oct 6, 2020 | Takeda | Business Decision (no safety or efficacy concerns) | Safety / toxicity |
| NCT00794417 | A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in… | Phase 1 / Phase 2 | terminated | Nov 20, 2008 | Regeneron Pharmaceuticals | not stated | Not stated |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14… | Phase 2 | withdrawn | Jul 8, 2020 | Novartis Pharmaceuticals | company decision | Sponsor / business decision |
| NCT00269828 | A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received…(PIONEER) | Phase 3 | terminated | Dec 26, 2005 | CTI BioPharma | not stated | Not stated |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC…(N3) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2017 | Royal Marsden NHS Foundation Trust | Withdrawal of financial support from funder | Funding |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care… | Phase 2 | withdrawn | Feb 13, 2020 | SWOG Cancer Research Network | The pharmaceutical company sold the compound and pulled out. | Sponsor / business decision |
| NCT03553550 | Role of Circulating Tumor DNA (ctDNA) From LIquid Biopsy in Early Stage NSCLC Resected…(LIBERTI) | — | terminated | Jun 12, 2018 | Addario Lung Cancer Medical Institute | Enrollment futility | Efficacy / futility |
| NCT02762877 | Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma… | — | terminated | May 5, 2016 | Genomic Health®, Inc. | Business decision | Sponsor / business decision |
| NCT04044170 | Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Phase 2 | terminated | Aug 5, 2019 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer…(DOMINATION) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant… | Phase 2 | withdrawn | Apr 10, 2014 | Array Biopharma, now a wholly owned subsidiary of Pfizer | Study never started - transferred to Array. | Other (stated, no rule matched) |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung… | Phase 2 | withdrawn | Oct 9, 2018 | Stephanie Smiddy | No patients available | Other (stated, no rule matched) |
| NCT03302247 | Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy | Phase 2 | terminated | Oct 5, 2017 | Fox Chase Cancer Center | Unable to accrue subjects | Enrollment / accrual |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin…(NeoFIND) | Phase 2 | terminated | Oct 30, 2018 | Advanced Accelerator Applications | Recruitment was stopped before the target sample size was achieved. | Enrollment / accrual |
| NCT02318368 | A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects…(FOCAL) | Phase 2 | terminated | Dec 17, 2014 | AVEO Pharmaceuticals, Inc. | Sponsor's decision | Sponsor / business decision |
| NCT00576225 | CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | Phase 3 | withdrawn | Dec 19, 2007 | CTI BioPharma | not stated | Not stated |
| NCT01188707 | A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung… | Phase 1 / Phase 2 | terminated | Aug 25, 2010 | Herlev Hospital | Dose over MTD reached | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02642939 | Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic… | Phase 2 | terminated | Dec 30, 2015 | Check, Jerome H., M.D., Ph.D. | Lack of enrollment | Enrollment / accrual |
| NCT03945227 | Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus… | Phase 2 | withdrawn | May 10, 2019 | Yonsei University | Due to the delay in the study shceduled, due to the start of competitive study and the approval of… | Safety / toxicity |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With…(TRAP) | Phase 1 | terminated | Jan 8, 2014 | Polaris Group | not stated | Not stated |
| NCT02145078 | Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV… | N/A | terminated | May 22, 2014 | Barbara Ann Karmanos Cancer Institute | Slow accrual. | Enrollment / accrual |
| NCT01532362 | Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T… | N/A | terminated | Feb 14, 2012 | Jonsson Comprehensive Cancer Center | Drug sponsor stopped drug manufacture due to toxicity issues from other studies | Safety / toxicity |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT03382912 | Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line…(Cypress 2) | Phase 2 | terminated | Dec 26, 2017 | Eli Lilly and Company | The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit… | Other (stated, no rule matched) |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | Phase 2 | withdrawn | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Funding unavailable | Funding |
| NCT02346955 | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in… | Phase 1 | terminated | Jan 27, 2015 | Famewave Ltd. | not stated | Not stated |
| NCT02147990 | Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant…(NSCLC) | Phase 2 | terminated | May 28, 2014 | Clovis Oncology, Inc. | Sponsor discontinued development of CO-1686 for NSCLC. | Other (stated, no rule matched) |
| NCT04510415 | Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI | Phase 1 | terminated | Aug 12, 2020 | Hanmi Pharmaceutical Company Limited | Study termination by the Sponsor | Other (stated, no rule matched) |
| NCT01526928 | Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in… | Phase 1 / Phase 2 | terminated | Feb 6, 2012 | Clovis Oncology, Inc. | not stated | Not stated |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT02451865 | Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV… | Phase 1 | withdrawn | May 22, 2015 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT02412371 | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With… | Phase 1 / Phase 2 | terminated | Apr 9, 2015 | AbbVie | Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable… | Other (stated, no rule matched) |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab…(RATIONALE001) | Phase 3 | terminated | Nov 19, 2018 | Celgene | BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound,… | Other (stated, no rule matched) |
| NCT00840749 | Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell…(STARS) | N/A | terminated | Feb 10, 2009 | Accuray Incorporated | Lack of enrollment | Enrollment / accrual |
| NCT02193152 | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | Phase 2 | terminated | Jul 17, 2014 | Washington University School of Medicine | Terminated by sponsor | Other (stated, no rule matched) |
| NCT01857271 | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell…(EVENT) | Phase 2 | terminated | May 20, 2013 | Albert Einstein College of Medicine | low accrual | Enrollment / accrual |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or… | Phase 1 | terminated | Mar 12, 2015 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | This study did not meet the efficacy objective | Efficacy / futility |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy…(IDA) | Phase 3 | terminated | Dec 9, 2013 | Norwegian University of Science and Technology | Poor enrollment due to the introduction of immunotherapy | Enrollment / accrual |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants… | Phase 2 | withdrawn | Jul 13, 2016 | Eli Lilly and Company | To pursue broader program objectives in oncology. | Other (stated, no rule matched) |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid… | Phase 1 | terminated | Nov 17, 2017 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT04203511 | INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small… | Phase 3 | withdrawn | Dec 18, 2019 | Incyte Corporation | Sponsor Strategic/Business Decision | Sponsor / business decision |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | Phase 2 | terminated | Jan 26, 2018 | Agenus Inc. | Trial will not proceed due to changes in the treatment landscape. | Other (stated, no rule matched) |
| NCT03713099 | NEUWAVE Flexible Probe Study #2 | N/A | withdrawn | Oct 19, 2018 | Ethicon, Inc. | Changed study design prior to any patients enrolled. | Enrollment / accrual |
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | Phase 2 | terminated | Jan 11, 2007 | NewLink Genetics Corporation | Enrollment goals unable to be reached. | Enrollment / accrual |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | Phase 2 / Phase 3 | terminated | Jan 24, 2013 | NewLink Genetics Corporation | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 22, 2020source: clinicaltrials